26.1K
views
43
authors
7
articles
Editors
4
Impact
Loading...
6,272 views
16 citations
6,081 views
14 citations

Breast cancer is characterized by considerable metabolic diversity. A relatively high percentage of patients diagnosed with breast carcinoma do not respond to standard-of-care treatment, and alteration in metabolic pathways nowadays is considered one of the major mechanisms responsible for therapeutic resistance. Consequently, there is an emerging need to understand how metabolism shapes therapy response, therapy resistance and not ultimately to analyze the metabolic changes occurring after different treatment regimens. The most commonly applied neoadjuvant chemotherapy regimens in breast cancer contain an anthracycline (doxorubicin or epirubicin) in combination or sequentially administered with taxanes (paclitaxel or docetaxel). Despite several efforts, drug resistance is still frequent in many types of breast cancer, decreasing patients’ survival. Understanding how tumor cells rapidly rewire their signaling pathways to persist after neoadjuvant cancer treatment have to be analyzed in detail and in a more complex system to enable scientists to design novel treatment strategies that target different aspects of tumor cells and tumor resistance. Tumor heterogeneity, the rapidly changing environmental context, differences in nutrient use among different cell types, the cooperative or competitive relationships between cells pose additional challenges in profound analyzes of metabolic changes in different breast carcinoma subtypes and treatment protocols. Delineating the contribution of metabolic pathways to tumor differentiation, progression, and resistance to different drugs is also the focus of research. The present review discusses the changes in glucose and fatty acid pathways associated with the most frequently applied chemotherapeutic drugs in breast cancer, as well the underlying molecular mechanisms and corresponding novel therapeutic strategies.

3,760 views
12 citations
Open for submission
Frontiers Logo

Frontiers in Bioengineering and Biotechnology

Synthetic Biology and Metabolomics: Novel Insight in Oncology Research
Edited by Subhradip Karmakar, Manash K. Paul, Ruby Dhar
Deadline
30 June 2024
Submit a paper
Recommended Research Topics
Frontiers Logo

Frontiers in Oncology

Metabolic Plasticity of Cancer
Edited by Tuuli Käämbre, Rafael Moreno-Sánchez, Sara Rodriguez-Enriquez
97.8K
views
87
authors
15
articles
Frontiers Logo

Frontiers in Oncology

Tumor Metabolism in Cancer Therapy Resistance
Edited by Sara Granja, Marta Pojo, Céline Pinheiro
70.4K
views
59
authors
8
articles
Frontiers Logo

Frontiers in Oncology

Redox Metabolism: a Double Edge Sword Sustaining the Adaptive Resistance to Therapy in Cancer
Edited by Barbara Marengo, Cinzia Domenicotti, Jose Pedro Friedmann Angeli
20.5K
views
7
articles
Frontiers Logo

Frontiers in Oncology

Therapy Resistance in Tumor Microenvironment: Metabolic Reprogramming and Purinergic Signaling
Edited by Michele Zanoni, Elena Adinolfi, Henrique Borges da Silva
19K
views
21
authors
6
articles
Frontiers Logo

Frontiers in Oncology

Targeting Tumor Microenvironment and Metabolic Reprogramming in Triple-negative Breast Cancer
Edited by Weipeng Zhao, Lili Yang, Shengyu Yang
17.4K
views
57
authors
5
articles